Document is current
Any future updates will be listed below
-
Authors
Hoepken, Bengt https://orcid.org/0000-0002-7487-8559
Serrano, Daniel
Harris, Kristina
Hwang, Mark C. https://orcid.org/0000-0003-2160-1481
Reveille, John
-
Funding
Funding for this research was provided by:
UCB Pharma, the manufacturer of certolizumab pegol
- License Information
-
More Information
Article History
Accepted: 19 October 2020
First Online: 31 October 2020
Compliance with ethical standards
:
: BH is an employee of UCB Pharma. DS is an employee of Pharmerit International, which received funds to conduct the study. KH was an employee of UCB Pharma at the time the study was conducted. MCH is supported by the UTHealth Center for Clinical and Translational Sciences Kl2 Program (1KL2-TR-003168–01). JDR has consulted in the past year for UCB Pharma, Eli Lilly and Novartis, has received a research grant from the Janssen Pharmaceutical Division of Johnson & Johnson and is engaged in a clinical trial with Pfizer, Inc.
: This was a non-interventional validation study to evaluate the psychometric performance of the ASQoL within a patient population with nr-axSpA.
: Not directly applicable for this validation study, which used patient data from a completed clinical trial; informed consent was obtained from all patients who participated in the original clinical trial (RAPID-axSpA) at the time the study was conducted.
